BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SKBBY catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:fea132d82a235f875270@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:SKBBY P3 readout (est.): A166
DESCRIPTION:A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patient
 s With HER2-Positive Unresectable or Metastatic Breast Cancer Previously T
 reated With Trastuzumab and Taxane Therapy\nNCT06968585 | PHASE3 | ACTIVE_
 NOT_RECRUITING | sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Lt
 d.\nPrimary completion date (ESTIMATED)\; top-line results usually follow 
 later.\nTicker SKBBY (confidence 0.6)\nSource: https://clinicaltrials.gov/
 study/NCT06968585\nScheduling/reference data from public records\; dates c
 an move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06968585
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c16df92ac8e247c21e44@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SKBBY P3 readout (est.): A Study of SKB264 in Combination With Pemb
 rolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-L
 ine Treatment for PD-L1 Negative Patients With Locally Advanced or Metasta
 tic Non-Squamous Non-Small Cell Lung Cancer
DESCRIPTION:A Study of SKB264 in Combination With Pembrolizumab Versus Chem
 otherapy in Combination With Pembrolizumab as First-Line Treatment for PD-
 L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-
 Small Cell Lung Cancer\nNCT06711900 | PHASE3 | ACTIVE_NOT_RECRUITING | spo
 nsor: Sichuan Kelun-Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completi
 on date (ESTIMATED)\; top-line results usually follow later.\nDate precisi
 on: month (shown on the first day)\nTicker SKBBY (confidence 0.6)\nSource:
  https://clinicaltrials.gov/study/NCT06711900\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06711900
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:22ee89318718b167ffd8@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:SKBBY P2 readout (est.): SKB264 Monotherapy in Selected Subjects Wi
 th Advanced Solid Tumors
DESCRIPTION:SKB264 Monotherapy in Selected Subjects With Advanced Solid Tum
 ors\nNCT05631262 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Kelun
 -Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nTicker SKBBY (confidence 0.6)\n
 Source: https://clinicaltrials.gov/study/NCT05631262\nScheduling/reference
  data from public records\; dates can move. Not investment\, legal or medi
 cal advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05631262
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:851e2d368efc4ca6fc04@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SKBBY P1/P2 readout (est.): A Study of KL590586 in Patients With Ad
 vanced Solid Tumors
DESCRIPTION:A Study of KL590586 in Patients With Advanced Solid Tumors\nNCT
 05265091 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sichuan Kelun-
 Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completion date (ESTIMATED)\
 ; top-line results usually follow later.\nTicker SKBBY (confidence 0.6)\nS
 ource: https://clinicaltrials.gov/study/NCT05265091\nScheduling/reference 
 data from public records\; dates can move. Not investment\, legal or medic
 al advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05265091
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6458fcf9bae4318253ee@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SKBBY P3 readout (est.): Study of SKB264 for Locally Advanced\, Rec
 urrent or Metastatic HR+/HER2- Breast Cancer
DESCRIPTION:Study of SKB264 for Locally Advanced\, Recurrent or Metastatic 
 HR+/HER2- Breast Cancer\nNCT06081959 | PHASE3 | RECRUITING | sponsor: Sich
 uan Kelun-Biotech Biopharmaceutical Co.\, Ltd.\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nTicker SKBBY (confiden
 ce 0.6)\nSource: https://clinicaltrials.gov/study/NCT06081959\nScheduling/
 reference data from public records\; dates can move. Not investment\, lega
 l or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06081959
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
